Methods of treating skin cancer by administering a PD-1 inhibitor
First Claim
Patent Images
1. A method of treating or inhibiting the growth of a tumor comprising:
- (a) selecting a patient with cutaneous squamous cell carcinoma (CSCC); and
(b) administering to the patient a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds PD-1, wherein the therapeutically effective amount is administered once every two weeks in a dose comprising 1 to 3 mg/kg of the patient'"'"'s body weight;
wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO;
1 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO;
2.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.
88 Citations
18 Claims
-
1. A method of treating or inhibiting the growth of a tumor comprising:
-
(a) selecting a patient with cutaneous squamous cell carcinoma (CSCC); and (b) administering to the patient a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds PD-1, wherein the therapeutically effective amount is administered once every two weeks in a dose comprising 1 to 3 mg/kg of the patient'"'"'s body weight; wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO;
1 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO;
2. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
Specification